Somatostatin Analogs: A Guide to Somatostatin, Cortistatin, and SSTR Pharmacology

Somatostatin exists in two active forms: somatostatin-14 (SST-14), a 14-amino-acid cyclic peptide, and somatostatin-28 (SST-28), an N-terminally extended 28-amino-acid form. Both are cleaved from a common preprohormone precursor by prohormone convertases, with SST-14 dominant in brain and SST-28 enriched in gut and pancreas. The core SSTR-binding pharmacophore is the Phe7-Trp8-Lys9-Thr10 tetrapeptide constrained within a disulfide-stabilized loop.

The hormone's canonical role was defined in the hypothalamus, where periventricular nucleus somatostatin neurons project to the median eminence and release SST into portal circulation to inhibit pituitary GH secretion — balancing the stimulatory drive of GHRH and producing the pulsatile GH profile observed in healthy adults. Loss of this inhibitory tone contributes to the sustained GH hypersecretion of acromegaly.

Beyond the GH axis, SST is expressed in pancreatic D-cells (where it locally inhibits insulin and glucagon), gastric and intestinal D-cells (suppressing gastrin, secretin, CCK, and VIP), adrenal medulla, thyroid C-cells, and many CNS regions where it acts as a neuromodulator alongside classical neurotransmitters. SST neurons in hippocampus and cortex are depleted in Alzheimer's disease brain at postmortem, consistent with a broader role in cognitive function that remains incompletely understood.

Five somatostatin receptor subtypes (SSTR1, SSTR2, SSTR3, SSTR4, SSTR5) are each encoded by a separate gene and belong to the class A GPCR family, all coupling primarily to Gi/o to inhibit adenylyl cyclase and reduce intracellular cAMP. SSTR2 exists as two alternatively spliced variants (SSTR2A and SSTR2B). Tissue distribution varies substantially across subtypes.

SSTR1 is expressed in brain, GI tract, and some pituitary adenomas; its role is still being clarified. SSTR2 is the workhorse receptor for pituitary GH and TSH regulation, gastric and pancreatic hormone suppression, and is the principal target of octreotide and lanreotide — most of the anti-GH and anti-hormone effects of these analogs in clinical use are SSTR2-mediated. SSTR2 also drives the antiproliferative signaling observed in neuroendocrine tumors. SSTR3 is present in pituitary, spleen, and brain, with an increasingly recognized role in ciliary signaling. SSTR4 is the most restricted, concentrated in brain (hippocampus, cortex) and some peripheral nerves.

SSTR5 is expressed in pituitary, pancreas, and gut. In corticotroph adenomas (Cushing's disease), SSTR5 becomes the dominant receptor subtype — which is why pasireotide, with its broader SSTR1/2/3/5 affinity and high SSTR5 binding, is preferred over octreotide for Cushing's disease. Receptor subtype profiling of individual tumors (by immunohistochemistry or Ga-68 DOTATATE PET imaging) increasingly guides analog selection in NET practice.

Cortistatin was discovered in 1996 by de Lecea and colleagues during a screen for cortical sleep-regulating peptides. It exists as cortistatin-14 and cortistatin-29 in humans (the longer form is the dominant brain species), and shares 11 of 14 amino acids with somatostatin-14 — including the core Phe-Trp-Lys-Thr pharmacophore. Despite this sequence overlap, cortistatin is expressed from a separate gene (CORT) under distinct transcriptional control and in largely different tissues: cortical GABAergic interneurons, hippocampus, and immune cells rather than hypothalamus and gut.

Pharmacologically, cortistatin binds SSTR1–5 with affinities comparable to somatostatin, producing overlapping endocrine effects when administered systemically. Two additional binding partners distinguish cortistatin: it activates the ghrelin receptor GHSR1a (with opposite physiology to ghrelin — cortistatin does not stimulate appetite) and interacts with MrgX2 on mast cells, relevant to inflammation research. Some evidence suggests a distinct cortistatin receptor, though this has not been fully characterized.

Functionally, cortistatin has been studied for sleep (enhances slow-wave sleep in rodents, effect on human sleep less established), anticonvulsant effects, anti-inflammatory actions in sepsis and autoimmune models, and suppression of Th17 responses. No cortistatin-based drug has reached clinical trials. It remains a research-grade peptide, studied primarily as a tool to interrogate SSTR and ghrelin-receptor signaling and a lead for potential anti-inflammatory therapeutics.

Native somatostatin-14 has a plasma half-life of approximately 1–3 minutes, reflecting rapid hydrolysis by circulating peptidases (notably in liver and kidney) at several exposed peptide bonds. This kinetic profile makes the native hormone unusable as a drug — an IV infusion at the doses needed to match therapeutic analog exposures would require continuous administration and produce erratic hormonal swings.

Synthetic analogs extend the half-life primarily through three strategies: backbone shortening (reducing the 14-residue peptide to an 8-residue cyclic core that retains pharmacophore but reduces peptidase substrate surface), disulfide stabilization (the native SST-14 disulfide is preserved but reinforced), and D-amino-acid substitutions at cleavage-susceptible positions. Octreotide introduced D-Phe and D-Trp residues; lanreotide maintains broadly similar modifications; pasireotide uses a cyclohexapeptide scaffold with different D-amino-acid content to shift receptor selectivity toward SSTR5.

The resulting half-lives extend from 1–3 minutes (native SST) to 90–120 minutes (subcutaneous octreotide) and, with depot formulations, to effective multiweek to multimonth coverage. Octreotide LAR achieves roughly 28-day coverage with monthly dosing; lanreotide autogel/depot similarly targets monthly administration; pasireotide LAR extends to every 4 weeks. These half-life extensions are what made somatostatin-targeted therapy clinically practical.

Three somatostatin analogs dominate current clinical practice. Octreotide (Sandostatin) is the first-generation SSTR2/5-selective analog approved in 1988 for acromegaly, carcinoid syndrome, and VIPoma. It is available as short-acting subcutaneous octreotide (multiple daily doses) and long-acting release (Sandostatin LAR, monthly intramuscular depot). Octreotide remains the most-used analog globally, with generic and biosimilar competition in recent years.

Lanreotide (Somatuline Depot) is a structurally similar SSTR2/5-selective cyclic octapeptide, formulated as a deep subcutaneous injection delivered from a prefilled syringe. The CLARINET trial established lanreotide's role in slowing progression of enteropancreatic NETs, and it is approved for acromegaly and carcinoid syndrome in the US and EU. For most hormonal-control indications, octreotide and lanreotide are broadly interchangeable, with differences emerging in patient preference (device, injection volume, self-administration option) and specific subgroup outcomes.

Pasireotide (Signifor) is a second-generation multi-SSTR agonist with affinity for SSTR1, 2, 3, and 5, and particularly high SSTR5 binding. This broader receptor profile drives its approval for Cushing's disease (SSTR5-driven corticotroph adenomas) and for acromegaly refractory to first-generation analogs. The trade-off is hyperglycemia: pasireotide inhibits insulin secretion more strongly than octreotide because SSTR5 is expressed on pancreatic beta cells, and a substantial fraction of patients develop diabetes or worsened glycemic control on therapy.

Selection among these three analogs depends on indication, receptor-subtype expression on the individual tumor, prior response history, and metabolic comorbidities. See the octreotide vs lanreotide vs pasireotide comparison for the full treatment-selection framework.

Somatostatin analogs are entrenched as first-line medical therapy for three indications: acromegaly (after unsuccessful transsphenoidal surgery or as primary therapy for surgical-ineligible patients), neuroendocrine-tumor hormonal control and antiproliferative therapy, and Cushing's disease (pasireotide specifically). Lutetium-177 DOTATATE extends the somatostatin-analog franchise into peptide radioligand therapy for SSTR2-positive midgut NETs.

The research frontier includes subtype-selective SSTR antagonists (which paradoxically work well for radioligand imaging because receptors are not internalized away from the cell surface), oral formulations of existing analogs (octreotide oral capsule MYCAPSSA was approved in 2020 for acromegaly maintenance), and combination regimens pairing analogs with mTOR inhibitors (everolimus) or tyrosine-kinase inhibitors (sunitinib) for progressive NETs.

Cortistatin therapy remains preclinical. Anti-inflammatory applications in inflammatory bowel disease, arthritis, and sepsis have been explored in animal models but no human clinical program has matured. The ghrelin-receptor interaction of cortistatin complicates drug-development strategy — a cortistatin agonist would need to avoid ghrelin-mediated metabolic effects or select for brain versus peripheral exposure. For the research community, cortistatin remains primarily a pharmacological tool rather than a clinical lead.